Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies

Recent advances in genome modification technology coupled with the longstanding clinical success of hematopoietic stem and progenitor cells (HSPCs) warrants great optimism for the next generation of engineered HSPC-based therapies.